Logic-gated nanoregulators: A paradigm shift from drug delivery to pre-programmed multi-target immunotherapy.

Abstract

Cancer immunotherapy has reshaped oncology, yet its broad application is constrained by an immunosuppressive tumor microenvironment and the systemic toxicities of conventional treatments. This review traces the evolution of nanomedicine from a passive drug delivery vehicle to a therapeutic program encoded in a physical structure. The tumor microenvironment poses physical and cellular barriers that operate not as independent hurdles but as self-reinforcing systems, an architecture that dictates a target-selection logic whereby nanocarriers must engage paired targets simultaneously rather than sequentially. This logic translates into three coupled engineering requirements, namely co-loading of physicochemically diverse agents, spatial coordination across subcellular compartments, and temporal synchronization of release. Pre-programmed stimuli-responsive systems embody the current capability for meeting these demands. The boundary between pre-programmed computation and adaptive feedback is further evaluated, with the latter defined by the capacity to sense therapeutic outcomes and modulate subsequent release, a feat that remains unrealized in vivo. Finally, three translational challenges are assessed, all converging on whether the execution of a nanocarrier's therapeutic program can be trusted in the patient. Trust becomes possible when the carrier's trajectory hinges on biological processes conserved across patients, when its fabrication preserves the structural features encoding its function, and when its material composition dictates a predictable clearance pathway. These are not translational afterthoughts but the design constraints that will determine whether the next generation of cancer nanomedicines fulfills its clinical promise.